Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)

NCT01590225 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: Boceprevir
DRUG: Peginterferon alpha-2b
DRUG: Ribavirin
DRUG: Boceprevir
DRUG: Peginterferon alfa-2b
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC